🏛️ Verified NIH Record • Updated 2026-07-23
Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) (NCT04816604)
An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Gossamer Bio USA, Inc.
🩺 Plain-English Summary (8th-Grade Level)
This open-label extension study will evaluate the long-term effects of GB002 (seralutinib) in subjects who previously participated in a GB002 PAH study.
Who can join: Review the eligibility criteria below.
Location: University of California, Davis Medical Center — Sacramento, California
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (28 Sites)
Showing the first 25 of 28 sites.
- University of California, Davis Medical Center — Sacramento, California
- Medical Corporation — Santa Barbara, California
- Mayo Clinic — Jacksonville, Florida
- Cleveland Clinic Florida — Weston, Florida
- University of Kansas Medical Center — Kansas City, Kansas
- Norton Pulmonary Specialists — Louisville, Kentucky
- Tufts Medical Center — Boston, Massachusetts
- University of Nebraska Medical Center — Omaha, Nebraska
- NYU Langone Health — New York, New York
- New York Presbyterian Hospital - Weill Cornell Medicine — New York, New York
- University of Rochester Medical Center — Rochester, New York
- The Ohio State University Wexner Medical Center — Columbus, Ohio
- INTEGRIS Baptist Medical Center, Inc. — Oklahoma City, Oklahoma
- Houston Methodist Hospital — Houston, Texas
- University of Utah Health — Salt Lake City, Utah
- Royal Hobart Hospital — Hobart, Tasmania
- St. Vincent's Hospital Melbourne — Fitzroy, Victoria
- Všeobecná fakultní nemocnice v Praze — Prague,
- AP-HP Hôpital de Bicêtre — Le Kremlin-Bicêtre,
- DRK Kliniken Berlin — Berlin,
- Universitaetsklinikum Giessen und Marburg GmbH - Medizinische Klinik IV und V — Giessen,
- Klinik für Pneumologie, Klinisches Studienzentrum Medizinische Hochschule — Hanover,
- Thoraxklinik-Heidelberg gGmbH — Heidelberg,
- Klinik und Poliklinik f. Innere Medizin II Universitätsklinikum Regensburg — Regensburg,
- Hospital Universitario 12 de Octubre — Madrid,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pulmonary Arterial Hypertension
- A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION) — Aurora, Colorado
- A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension — Phoenix, Arizona
- Pulmonary Vascular Disease Phenomics Program PVDOMICS — Tucson, Arizona
- An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) — Jacksonville, Florida
- A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension — Aurora, Colorado
- ADAPT - A Patient Registry of the Real-world Use of Orenitram® — Fresno, California
Explore by condition: All Pulmonary Arterial Hypertension clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.